Literature DB >> 4614670

Natural history of mouse syngeneic lymphoma. Morphologic and immunologic aspects.

M Jurin, B Drewinko.   

Abstract

The morphologic changes in lymphoreticular tissues and development of antitumor immune reactions of specific pathogen-free mice injected with syngeneic lymphoma cells were sequentially analyzed. The regional (right inguinal) lymph node demonstrated mild changes indicative of immunologic response. Systemic lymph nodes revealed a moderate degree of immune response on morphologic basis. The spleen was the site of marked activity, characterized by the presence of large pyroninophilic cells and germinal centers. Foci of necrosis in the local tumor accompanied by mature lymphocytes suggested cell-mediated immune rejection. Mice developed circulating antibodies 2 days after implantation. No antibodies were demonstrated attached to fresh tumor cells. Lymphocyte cytotoxic activity was demonstrated beginning on day 4. Both cytotoxic activity and circulating antibodies were no longer detectable after the third week following tumor implantation. Tumor-bearing mice also had an impaired capacity to mount a primary immune reaction to sheep red blood cells. The spleen demonstrated a marked loss of lymphocytes and the subsequent appearance of masses of amyloid material. It is suggested that amyloidosis in lymphoreticular organs is the result of a derangement in the immune response of the host following a prolonged and sustained antigenic stimulation. It appears that in syngeneic pathogen-free mice the spleen plays the major role in immune rejection mechanisms while the draining node only plays a modest role.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4614670      PMCID: PMC1910916     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  44 in total

1.  AMYLOIDOSIS AND LYMPHOID APLASIA IN MOUSE RADIATION CHIMERAS.

Authors:  S BRADBURY; H S MICKLEM
Journal:  Am J Pathol       Date:  1965-02       Impact factor: 4.307

2.  CELLULAR AND HUMORAL PHENOMENA DURING THE INDUCTIVE PHASE OF PARABIOSIS TOLERANCE.

Authors:  R A MCBRIDE; M SIMONSEN
Journal:  Transplantation       Date:  1965-03       Impact factor: 4.939

3.  Auto-immunity and aging.

Authors:  R L WALFORD
Journal:  J Gerontol       Date:  1962-07

4.  Quantitative studies on tissue transplantation immunity. II. The origin, strength and duration of actively and adoptively acquired immunity.

Authors:  R E BILLINGHAM; L BRENT; P B MEDAWAR
Journal:  Proc R Soc Lond B Biol Sci       Date:  1954-12-15

5.  Transfer of resistance to tumor with lymphoid cells from immunized allogeneic donors.

Authors:  M Jurin; H D Suit
Journal:  Tex Rep Biol Med       Date:  1973

6.  Delayed hypersensitivity to chemically induced tumors in mice and correlation with an in vitro test.

Authors:  W J Halliday; M Webb
Journal:  J Natl Cancer Inst       Date:  1969-07       Impact factor: 13.506

7.  Changes in lymphoreticular tissues during growth of a murine adenocarcinoma. I. Histology and weight of lymph nodes, spleen, and thymus.

Authors:  A J Edwards; M R Sumner; G F Rowland; C M Hurd
Journal:  J Natl Cancer Inst       Date:  1971-08       Impact factor: 13.506

8.  Tumor-specific antigen(s) in a spontaneous mammary carcinoma of C3H mice. I. Quantitative cell transplants into mammary-tumor-agent-positive and -free mice.

Authors:  V Silobrcic; H D Suit
Journal:  J Natl Cancer Inst       Date:  1967-12       Impact factor: 13.506

9.  Possible host resistance in carcinoma of the breast: a histological study.

Authors:  I M Hamlin
Journal:  Br J Cancer       Date:  1968-09       Impact factor: 7.640

10.  Delayed hypersensitivity. III. Specific desensitization of guinea pigs sensitized to protein antigens.

Authors:  J W UHR; A M PAPPENHEIMER
Journal:  J Exp Med       Date:  1958-12-01       Impact factor: 14.307

View more
  1 in total

1.  Macrophages and lymphoid tissues in mice with concomitant tumour immunity.

Authors:  D S Nelson; R Kearney
Journal:  Br J Cancer       Date:  1976-09       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.